SEBI has halted Par Drugs and Chemicals' proposed slump sale of its core business to Phal-Jig Fine Chemicals, a promoter-related entity, citing irregularities in valuation and shareholder communication. The regulator has ordered an independent re-evaluation of the business and a fairness opinion.